Specific Bioactive Collagen Peptides reduce knee joint discomfort in young physically active adults

Date: 15.02.2021Source: Gelita

The randomised controlled trial rigorously showed the benefits of GELITA’s FORTIGEL in reducing the intensity of knee joint pain during activity, in healthy men and women.

Knee pain is a common exercise complaint. Many physical activities can put strain on the knees, causing activity-related joint discomfort, which impairs performance and reduces training gains. In the recent study from the University of Freiburg, Zdzieblik et al. (2021) investigated the benefits of FORTIGEL, the specific BCP (Bioactive Collagen Peptides) from GELITA, optimised to regenerate cartilage, maintain joint mobility, and minimise joint discomforts

The study involved 180 physically active young men and women, reporting knee joint discomfort with physical activity, who supplemented with only 5 g of FORTIGEL or a maltodextrin placebo, for 12 weeks. The primary outcome from the study showed that supplementation with FORTIGEL resulted in statistically significant reduction in ‘pain during activity’ compared with the placebo, as assessed by both the study participants and the physician. According to the authors of the study, this “may help to prevent the clinical manifestation of chronic degenerative joint diseases”.

These results confirm the previous findings from Zdzieblik et al. (2017), the first to observe a significant reduction in activity-related joint discomfort from the use of FORTIGEL compared with placebo, in a RCT involving 139 active men and women.

Said Dr. Stephan Hausmanns, GELITA’s Vice President for Health & Nutrition: “FORTIGEL is the most clinically-studied Bioactive Collagen Peptides, for 30 years. Over 20 studies, involving more than 2,500 participants, contributed to develop FORTIGEL and prove the product’s positive effects to joint health. So far, no other collagen peptide solution on the market has been able to offer an alternative to FORTIGEL, backed by science.” For more visit mdpi.com/2072-6643/13/2/523/pdf

David Cox / IDM

Print article (with images) Print article (without images)


Always stay up to date and sign up for our newsletter service: